Aurobindo Pharma

Aurobindo Pharma reported a resilient financial performance in the third quarter, posting an 8 percent increase in net profit to Rs 910 crore. The improvement was driven by stable demand across key international markets, disciplined cost management, and a favorable product mix. While pricing pressure persisted in certain geographies, operational efficiencies and sustained traction in core therapeutic segments supported earnings growth.

Aurobindo Pharma has announced plans to acquire an additional stake in one of its joint venture entities, signaling a strategic move to deepen operational control and strengthen its business portfolio. The transaction reflects the company’s focus on consolidating key assets and enhancing long-term value creation. By increasing its ownership, Aurobindo aims to streamline decision-making, improve integration, and capture a larger share of future earnings from the venture.

Aurobindo Pharma reported a 10% year-on-year decline in consolidated net profit for the first quarter of FY26, amounting to Rs. 824 crore. The fall in profit was primarily attributed to increased research and development expenditure and a rise in overall operating costs. Despite the dip in bottom-line performance, the company's revenue rose to Rs. 7,478 crore, marking a 16.5% increase compared to the same period last year.

Aurobindo Pharma is set to commence manufacturing of a long-acting injectable HIV treatment, marking a pivotal move in the evolving landscape of antiretroviral therapies. This development underscores the company’s ambition to advance beyond conventional generic formulations and deepen its foothold in complex, high-value drug segments. By investing in innovative delivery systems that reduce dosing frequency, Aurobindo aims to address critical adherence challenges in HIV care while capturing emerging global demand.

Indian pharmaceutical equities plunged on June 17, as investor sentiment deteriorated following US President Donald Trump’s renewed threat to impose tariffs on pharmaceutical imports. The Nifty Pharma index dropped over 2%, marking it as the day’s worst-performing sector. With India being one of the largest exporters of generic drugs to the US, analysts fear a significant impact on margins, revenues, and forward guidance for key industry players. Major firms like Cipla, Dr.

Aurobindo Pharma reported a slight decline in consolidated net profit for the quarter ended March 2025, registering Rs 903 crore compared to Rs 907 crore in the same period the previous year. Despite the minor quarterly dip, the Hyderabad-based pharmaceutical major closed the financial year on a strong note, with annual profit rising 10% to Rs 3,484 crore and revenue reaching an all-time high of Rs 31,724 crore. The company credits its strong performance to robust European operations, volume-led growth, and a diverse product portfolio.

Aurobindo Pharma, a prominent player in the pharmaceutical industry, announced that operations at its subsidiary Lyfius Pharma’s plant in Kakinada, Andhra Pradesh, have been temporarily suspended following a fire incident on April 27, 2025. Although the fire caused damage to some ancillary equipment, the core manufacturing infrastructure at the Penicillin-G production facility was unaffected. No injuries were reported, and the company is working diligently to assess the damage and facilitate the necessary repairs.

Aurobindo Pharma Ltd. has disclosed that the U.S. Food and Drug Administration (USFDA) issued a Form 483 with 11 procedural observations following a recent inspection of its North Carolina-based manufacturing unit, operated by its wholly owned subsidiary, Aurolife Pharma LLC. Conducted between March 24 and April 10, 2025, the inspection concluded with compliance concerns that, while non-critical, have prompted the company to implement corrective actions.